Resources from the same session
1241MO - Osimertinib (osi) after definitive chemoradiotherapy (CRT) in unresectable (UR) stg III EGFRm NSCLC: Analyses of CNS and distant progression from the phase III LAURA study
Presenter: Shun Lu
Session: Mini oral session 2: Non-metastatic NSCLC
Resources:
Abstract
Slides
Webcast
1206MO - ALINA: Exploratory biomarker analyses in patients (pts) with resected ALK+ non-small cell lung cancer (NSCLC) treated with adjuvant alectinib vs chemotherapy (chemo)
Presenter: Ben Solomon
Session: Mini oral session 2: Non-metastatic NSCLC
Resources:
Abstract
Slides
Webcast
1207MO - Neoadjuvant nivolumab monotherapy for high-risk clinical stage I non-small cell lung cancer: A phase II POTENTIAL study
Presenter: Yasuhiro Tsutani
Session: Mini oral session 2: Non-metastatic NSCLC
Resources:
Abstract
Slides
Webcast
1208MO - Phase III trial of perioperative pirfenidone therapy for lung cancer with idiopathic pulmonary fibrosis (IPF): NEJ034 study
Presenter: Yukinobu Goto
Session: Mini oral session 2: Non-metastatic NSCLC
Resources:
Abstract
Slides
Webcast
1242MO - The addition of belomethason propionate inhalation to radical radiotherapy for patients with locally advanced non-small cell lung cancer: A randomized controlled, open-label phase II study
Presenter: JIE ZHANG
Session: Mini oral session 2: Non-metastatic NSCLC
Resources:
Abstract
Slides
Webcast
1243MO - A phase III study comparing weekly carboplatin plus nab-paclitaxel and daily low-dose carboplatin for concurrent chemoradiotherapy in elderly patients (≥75 years) with unresectable locally advanced NSCLC: JCOG1914
Presenter: Shota Omori
Session: Mini oral session 2: Non-metastatic NSCLC
Resources:
Abstract
Slides
Webcast
Invited Discussant 1208MO, 1242MO and 1243MO
Presenter: Kersti Oselin
Session: Mini oral session 2: Non-metastatic NSCLC
Resources:
Slides
Webcast